In September 2025, the WHO added several GLP-1 drugs, including semaglutide and tirzepatide, to its Model List of Essential Medicines to improve global access to therapies used for diabetes and obesity-related conditions
doi: 10.1016/j.lfs.2020.118966 195 PetitJMVergsB
Datos de seguimiento del estudio STEP 4, publicado en JAMA en marzo y tambin informado por Healio, demostr que los adultos con obesidad que continuaron con 2,4 mg de semaglutida durante ms de 20 semanas experimentaron una prdida de peso continua o mantenimiento de peso en comparacin con los adultos que cambiaron a placebo
Seino, Y., Fukushima, M., Yabe, D
Thyroid Globulin Antibodies: Ideally, these should be less than 1 for a healthy state
Deciding to use GLP-1/GIP for weight loss should always involve careful advice from your doctor